Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

October 14, 2026

Agreement marks the Company’s second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

Performance

52-Week Range 58.9% below 52-week high

16.38

12.7352W Low 39.8952W High

1 Week 7.1% below 1-week high

15.591W Low 17.621W High

Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) traded between $12.73 and $39.89 over the past 52 weeks and last traded at $16.38, 58.9% below its 52-week high. Over the past week it ranged between $15.59 and $17.62.

Past 12 Months

+1.9%

+7.6%

-34.5%

-34.0%

-30.6%

-51.1%

1W +$0.30

1M +$1.16

3M -$8.64

6M -$8.43

YTD -$7.22

1Y -$17.09

RARE was -51.1% over the past year, -34.0% over six months, -30.6% year to date, +1.9% in the last week.

12 Months vs Market

RARE

-51.1%

DIA

+9.8%

SPY

+10.1%

QQQ

+7.9%

IWM

+13.8%

Over the past 12 months RARE returned -51.1% versus DIA (Dow) +9.8%, SPY (S&P 500) +10.1%, QQQ (Nasdaq 100) +7.9% and IWM (Russell 2000) +13.8%.

Volume & Liquidity 0.57× 3-mo avg

Today 2,399,591 3-mo avg 4.2M

3.1M

3.4M

4.2M

3.2M

YTD

2.8M

2.7M

RARE most recently traded 2,399,591 shares against a 3-month average daily volume of 4.2M.

More News

October 07, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

October 06, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

Ultragenyx (NASDAQ:RARE) Q2 Beats Estimates, Reaffirms Guidance as Shares Rise ↗

August 04, 2026

Via Chartmill

September 29, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

September 22, 2026

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

September 17, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

September 15, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

September 08, 2026

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

September 03, 2026

Via Chartmill

Thursday's session: top gainers and losers ↗

September 03, 2026

Via Chartmill

Gapping stocks in Thursday's session ↗

September 03, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

September 03, 2026

Via Chartmill

These stocks are moving in today's after hours session ↗

September 02, 2026

Via Chartmill

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

September 02, 2026

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

September 01, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 25, 2026

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy ↗

August 20, 2026

Via MarketBeat

August 19, 2026

Ultragenyx (RARE) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights ↗

August 04, 2026

Via MarketBeat

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

August 04, 2026

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

July 28, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 24, 2026